Dermatology
Vulvar Lichen Sclerosus
0
Pipeline Programs↗
6
Active Trials↗
1
Companies Involved↗
Vulvar Lichen Sclerosus is an early-stage landscape with 0 programs across 1 company. The most active players are MC2 Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
16
clinical trials
Completed8 · 50%
Recruiting4 · 25%
Terminated1 · 6%
Not yet recruiting1 · 6%
Unknown status1 · 6%
Active, not recruiting1 · 6%
Clinical Trials
Trial Activity
16 trials
StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms
Recruiting·—·Phase 1·NCT06662942·100 enrolled
Use of Platelet Rich Plasma from Cord Blood Vs Placebo in the Treatment of Vulvar Lichen Sclerosus
Recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 1/2·NCT06661382·100 enrolled
A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus
Active, not recruiting·—·Phase 1/2·NCT04967170·30 enrolled
Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.
Not yet recruiting·—·N/A·NCT07240389·45 enrolled
Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus
Completed·—·N/A·NCT03926299·66 enrolled
Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus
Completed·—·Phase 2·NCT00757874·56 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)